Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SPH5030 in HER2-positive or HER2-mutant biliary tract cancer and colorectal cancer
CTR20241487Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sph5030 in biliary cancer, colorectal adenocarcinoma, sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Started Jul 2024; status: completed.
02
Drugs
sph5030
03
Conditions
biliary cancercolorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20241487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241487.